As­cle­tis’ Gan­nex re­ports pos­i­tive in­ter­im PhII NASH da­ta af­ter scrap­ping pre­vi­ous mid-stage R&D plans

As­cle­tis’ sub­sidiary Gan­nex re­vealed that its non-al­co­holic steato­hep­ati­tis (NASH) drug can­di­date sig­nif­i­cant­ly re­duced av­er­age lev­els of liv­er fat in pa­tients en­rolled in a mid-stage tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER